You are here
News & Events
Vertex and Genomics plc Establish Collaboration to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines
Multi-year collaboration combines expertise in genomics, machine learning and drug discovery to identify novel targets for innovative medicines
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180829005676/en/
Genomics has developed a unique analysis engine, which uses genetics to understand human biology and the likely efficacy and safety of potential novel medicines. The Genomics engine is the largest of its kind in the world, with over 100 billion data points. It links human genetic variation at over 14 million positions in the human genome to changes in 7,000 molecular, cellular, and physiological measurements and disease outcomes. The company uses proprietary machine learning and statistical algorithms to predict the impact of therapeutic interventions.
“Human biology and genetics are a foundation of drug discovery at Vertex
and the team at Genomics brings together a unique combination of
sophisticated data science and human genetics,” said Dr.
“Human genetics has already been shown to have a substantial impact on
the success of novel drug targets. Our next generation of data and
algorithms promises to be transformative, not just for target discovery
but in biomarker selection and patient stratification,” said Professor
Scientists from Vertex and Genomics will work closely together to incorporate their deep understanding of human genetics into research and development related to target discovery and target validation in certain diseases. Both companies will also have the opportunity to suggest additional diseases for the collaboration, where human genetic evidence may be particularly powerful.
In addition to funding the resources committed by Genomics to the collaboration, Vertex will make milestone and royalty payments to the company for novel targets resulting from the collaboration that are taken through clinical development. Dr. Altshuler will also join the Genomics plc Board of Directors.
Additionally, Vertex has made a £10.5 million equity investment in
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in cystic fibrosis, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
Founded in 1989 in
For additional information and the latest updates from the company, please visit www.vrtx.com.
Every individual carries a unique set of genetic variants. Many of these variants change aspects of our biology. The powerful idea which underpins the company’s work is that to understand the consequences of a proposed drug one can look at individuals who happen to carry genetic variants which affect the same part of our biology as the drug. This human genetics approach allows Genomics to learn about human biology, directly, in humans, rather than having to rely on the model systems which lead to 90% of drug targets failing when they are tested in humans.
Backed by some of the leading investors in life sciences, Genomics has
an expert cross-disciplinary team of over 40 people, primarily
scientists and software engineers, with offices in
For additional information about
Special Note Regarding Forward-looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, including, without
limitation, Dr. Altshuler’s statements in the second paragraph of the
press release and Mr. Donnelly’s statements in the third paragraph of
the press release. While Vertex believes the forward-looking statements
contained in this press release are accurate, these forward-looking
statements represent the company's beliefs only as of the date of this
press release and there are a number of factors that could cause actual
events or results to differ materially from those indicated by such
forward-looking statements. Those risks and uncertainties include, among
other things, the risks listed under Risk Factors in Vertex's annual
report and quarterly reports filed with the
Michael Partridge, +1 617-341-6108
Eric Rojas, +1 617-961-7205
Zach Barber, +1 617-341-6470
Heather Nichols, +1 617-341-6992
Ben Atwell and Andrew Ward, +44 (0)20 3720 1000